JP2008507368A5 - - Google Patents

Info

Publication number

JP2008507368A5

JP2008507368A5 JP2007522850A JP2007522850A JP2008507368A5 JP 2008507368 A5 JP2008507368 A5 JP 2008507368A5 JP 2007522850 A JP2007522850 A JP 2007522850A JP 2007522850 A JP2007522850 A JP 2007522850A JP 2008507368 A5 JP2008507368 A5 JP 2008507368A5

Authority

JP

Japan

Prior art keywords

group

subject

change

alkyl

pharmaceutical composition

Prior art date

2005-07-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 230000008859 change Effects 0.000 claims 33
• 238000000034 method Methods 0.000 claims 33
• 125000000217 alkyl group Chemical group 0.000 claims 28
• 230000004199 lung function Effects 0.000 claims 26
• 239000008194 pharmaceutical composition Substances 0.000 claims 25
• 150000001875 compounds Chemical class 0.000 claims 22
• 125000003118 aryl group Chemical group 0.000 claims 20
• 229910052739 hydrogen Inorganic materials 0.000 claims 20
• 239000001257 hydrogen Substances 0.000 claims 20
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 16
• 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 16
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 16
• 125000000623 heterocyclic group Chemical group 0.000 claims 16
• 150000002431 hydrogen Chemical class 0.000 claims 16
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims 16
• 208000024891 symptom Diseases 0.000 claims 15
• 208000011623 Obstructive Lung disease Diseases 0.000 claims 14
• 125000003545 alkoxy group Chemical group 0.000 claims 12
• 125000004448 alkyl carbonyl group Chemical group 0.000 claims 12
• -1 carboxy, hydroxy Chemical group 0.000 claims 12
• 125000004438 haloalkoxy group Chemical group 0.000 claims 12
• 125000001188 haloalkyl group Chemical group 0.000 claims 12
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 11
• 208000006673 asthma Diseases 0.000 claims 9
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 8
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 8
• 229960001456 adenosine triphosphate Drugs 0.000 claims 8
• 125000003342 alkenyl group Chemical group 0.000 claims 8
• 125000004450 alkenylene group Chemical group 0.000 claims 8
• 125000002947 alkylene group Chemical group 0.000 claims 8
• 125000000304 alkynyl group Chemical group 0.000 claims 8
• 125000004419 alkynylene group Chemical group 0.000 claims 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
• 125000004093 cyano group Chemical group *C#N 0.000 claims 8
• 125000000392 cycloalkenyl group Chemical group 0.000 claims 8
• 125000000753 cycloalkyl group Chemical group 0.000 claims 8
• 229910052736 halogen Inorganic materials 0.000 claims 8
• 150000002367 halogens Chemical class 0.000 claims 8
• 125000003831 tetrazolyl group Chemical group 0.000 claims 8
• 239000003814 drug Substances 0.000 claims 7
• 229940124597 therapeutic agent Drugs 0.000 claims 6
• 230000002685 pulmonary effect Effects 0.000 claims 5
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
• 125000003710 aryl alkyl group Chemical group 0.000 claims 4
• 125000002102 aryl alkyloxo group Chemical group 0.000 claims 4
• 229910052799 carbon Inorganic materials 0.000 claims 4
• 125000004432 carbon atom Chemical group C* 0.000 claims 4
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
• 230000001939 inductive effect Effects 0.000 claims 4
• 230000002401 inhibitory effect Effects 0.000 claims 4
• 210000004126 nerve fiber Anatomy 0.000 claims 4
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
• 150000003839 salts Chemical class 0.000 claims 4
• 230000001953 sensory effect Effects 0.000 claims 4
• 125000001424 substituent group Chemical group 0.000 claims 4
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 4
• 229910052717 sulfur Inorganic materials 0.000 claims 4
• 125000004434 sulfur atom Chemical group 0.000 claims 4
• VQGBOYBIENNKMI-LJAQVGFWSA-N 5-[(3-phenoxyphenyl)methyl-[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid Chemical compound C1=C(C(O)=O)C(C(=O)O)=CC(C(O)=O)=C1C(=O)N([C@@H]1C2=CC=CC=C2CCC1)CC1=CC=CC(OC=2C=CC=CC=2)=C1 VQGBOYBIENNKMI-LJAQVGFWSA-N 0.000 claims 3
• 206010011224 Cough Diseases 0.000 claims 3
• 102000002294 Purinergic P2X Receptors Human genes 0.000 claims 3
• 108010000836 Purinergic P2X Receptors Proteins 0.000 claims 3
• 230000004913 activation Effects 0.000 claims 3
• 238000002347 injection Methods 0.000 claims 3
• 239000007924 injection Substances 0.000 claims 3
• 238000001990 intravenous administration Methods 0.000 claims 3
• 230000009467 reduction Effects 0.000 claims 3
• 230000001515 vagal effect Effects 0.000 claims 3
• 210000001186 vagus nerve Anatomy 0.000 claims 3
• 206010006451 bronchitis Diseases 0.000 claims 2
• 230000005764 inhibitory process Effects 0.000 claims 2
• 102000005962 receptors Human genes 0.000 claims 2
• 108020003175 receptors Proteins 0.000 claims 2
• 230000004044 response Effects 0.000 claims 2
• 206010006458 Bronchitis chronic Diseases 0.000 claims 1
• 201000003883 Cystic fibrosis Diseases 0.000 claims 1
• 206010014561 Emphysema Diseases 0.000 claims 1
• 241001465754 Metazoa Species 0.000 claims 1
• WFTMQZSSJCKHNN-JZBGLOBFSA-N P(Cl)(Cl)(Cl)(Cl)Cl.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 Chemical compound P(Cl)(Cl)(Cl)(Cl)Cl.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 WFTMQZSSJCKHNN-JZBGLOBFSA-N 0.000 claims 1
• 239000002253 acid Substances 0.000 claims 1
• 208000024716 acute asthma Diseases 0.000 claims 1
• UFZTZBNSLXELAL-IOSLPCCCSA-N adenosine 5'-[beta,gamma-methylene]triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O UFZTZBNSLXELAL-IOSLPCCCSA-N 0.000 claims 1
• 201000009267 bronchiectasis Diseases 0.000 claims 1
• 150000001768 cations Chemical class 0.000 claims 1
• 208000007451 chronic bronchitis Diseases 0.000 claims 1
• 238000002405 diagnostic procedure Methods 0.000 claims 1
• 238000000338 in vitro Methods 0.000 claims 1
• 238000001727 in vivo Methods 0.000 claims 1
• 239000000411 inducer Substances 0.000 claims 1
• 230000004941 influx Effects 0.000 claims 1
• 230000001404 mediated effect Effects 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 210000001640 nerve ending Anatomy 0.000 claims 1
• CAWZRIXWFRFUQB-IOSLPCCCSA-N α,β Methylene ATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CAWZRIXWFRFUQB-IOSLPCCCSA-N 0.000 claims 1